Kobayashi K, Taira N, Sawaki M, Sagawa N, Baba S, Saito T, Kawahara T, Hagiwara Y, Uemura Y, Shimozuma K, Ohashi Y, Mukai H. Patient-reported outcomes with trastuzumab monotherapy versus trastuzumab plus standard chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients (RESPECT): A randomized, open-label, phase 3 clinical trial. San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
Takahashi M, Sawaki M, Hagiwara Y, Uemura Y, Kawahara T, Shimozuma K, Ohashi Y, Saito T, Baba S, Kobayashi K, Mukai H, Taira N. Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial). San Antonio Breast Cancer Symposium 2018. San Antonio, the United States, December 2018.
Kashiwabara K, Matsuyama Y. Point and interval estimation in an efficient adaptive design of flexible sample size determination. At: Joint International Society for Clinical Biostatistics and Australian Statistical Conference 2018, Melbourne, Australia, 26–30 August, 2018. Abstr P4.
Hagiwara Y, Taira N, Saito T, Baba S, Kobayashi K, Kawahara T, Shiroiwa T, Fukuda T, Shimozuma K, Uemura Y, Mukai H, Ohashi Y, Sawaki M. The EQ-5D index of elderly patients with HER-2 positive breast cancer: results from the randomized N-SAS BC 07 trial for adjuvant trastuzumab with and without chemotherapy. International Society for Pharmacoeconomics and Outcome Research Asia Pacific 2018 Conference. Tokyo, Japan. September 2018. PCN65.
Hagiwara Y, Shinozaki T, Matsuyama Y. G-estimation of structural nested restricted mean time lost models to estimate effect of time-varying treatment on survival outcome. 29th International Biometric Conference. Barcelona, Spain. July 2018. CS41.1.
Yoshino T, Yamanaka T, Denda T,Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Shitara K. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: quality of life analysis. European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2018. Barcelona, Spain. June 2018.
Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H,
Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence
for metastatic colorectal cancer patients previously treated With fluoropyrimidine, oxaliplatin, and irinotecan— biomarker analysis. American Society of Clinical Oncology Annual Meeting 2018, Chicago, US, June 3, 2018. Abstract 3510.